Current approaches and future strategies for the implementation of pharmacogenomics in the clinical use of azole antifungal drugs

References

• Nocua-Báez LC, Uribe-Jerez P, Tarazona-Guaranga L, et al. Azoles de antes y ahora: una revisión [Azoles of then and now: a review]. Rev Chilena Infectol. 2020 Jun;37(3):219–230. Spanish. PMID: 32853312.
   PubMed Web of Science ®Google Scholar
• Ashbee HR, Gilleece MH. 2014. Chapter 38 - pharmacogenomics of antifungal agents. Handbook of Pharmacogenomics and Stratified Medicine, 879–900. 978-0-12-386882-4. DOI:10.1016/B978-0-12-386882-4.00038-4.
   Google Scholar
• Amsden JR, Gubbins PO. Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy. Expert Opin Drug Metab Toxicol. 2017 Nov;13(11):1135–1146. Epub 2017 Oct 20. PMID: 29022838.
   PubMed Web of Science ®Google Scholar
• Borobia AM, Dapia I, Tong HY, et al. Clinical implementation of pharmacogenetic testing in a hospital of the Spanish national health system: strategy and experience over 3 years. Clin Transl Sci. 2018 Mar;11(2):189–199. Epub 2017 Nov 28. PMID: 29193749; PMCID: PMC5866958.
   PubMed Web of Science ®Google Scholar
• Hippman C, Nislow C. Pharmacogenomic testing: clinical evidence and implementation challenges. J Pers Med. 2019 Aug 7;9(3):40. PMID: 31394823; PMCID: PMC6789586.
   PubMed Web of Science ®Google Scholar
• Mizzi C, Dalabira E, Kumuthini J, et al. Spectrum of pharmacogenomic biomarkers: implications for clinical pharmacogenomics. PLoS One. 2016 Sep 16;11(9):e0162866. Erratum in: PLoS One. 2017 Feb 16;12 (2):e0172595. PMID: 27636550; PMCID: PMC5026342.
   PubMed Web of Science ®Google Scholar
• Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012 Oct [Accesed 2020 Nov 13];92(4):414–417. PMID: 22992668; PMCID: PMC3660037. Available from: www.pharmgkb.org.
   PubMed Web of Science ®Google Scholar
• Saiz-Rodríguez M, Almenara S, Navares-Gómez M, et al. Effect of the most relevant CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates. Biomedicines. 2020 Apr 22;8(4):94. PMID: 32331352; PMCID: PMC7235792.
   PubMed Web of Science ®Google Scholar
• Darnaud L, Lamoureux F, Godet C, et al. Isavuconazole kinetic exploration for clinical practice. Drugs R D. 2018 Dec;18(4):317–321. PMID: 30306415; PMCID: PMC6277320.
   PubMed Web of Science ®Google Scholar
• Townsend R, Dietz A, Hale C, et al. Pharmacokinetic evaluation of CYP3A4-mediated drug-drug interactions of isavuconazole with rifampin, ketoconazole, midazolam, and ethinyl estradiol/norethindrone in healthy adults. Clin Pharmacol Drug Dev. 2017 Jan;6(1):44–53. Epub 2016 Jul 25. PMID: 27273461; PMCID: PMC5298035.
   PubMed Web of Science ®Google Scholar
• Shirasaka Y, Chang SY, Grubb MF, et al. Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions. Drug Metab Dispos. 2013 Aug;41(8):1566–1574. Epub 2013 May 30. PMID: 23723360; PMCID: PMC3716306.
   PubMed Web of Science ®Google Scholar
• Dapía I, García I, Martinez JC, et al. Prediction models for voriconazole pharmacokinetics based on pharmacogenetics: AN exploratory study in a Spanish population. Int J Antimicrob Agents. 2019 Oct;54(4):463–470. Epub 2019 Jul 4. PMID: 31279853.
   PubMed Web of Science ®Google Scholar
• Niwa T, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull. 2005 Sep;28(9):1805–1808. . PMID: 16141567.
   PubMed Web of Science ®Google Scholar
• Scordo MG, Aklillu E, Yasar U, et al. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol. 2001 Oct;52(4):447–450. PMID: 11678789; PMCID: PMC2014581.
   PubMed Web of Science ®Google Scholar
• García IG, Carcas AJ, Borobia AM. Strategy to effectively and efficiently implement voriconazole pharmacogenetics in clinical practice. Pharmacogenomics. 2020 Jul;21(10):647–649. Epub 2020 Jun 3. PMID: 32486895.
   PubMed Web of Science ®Google Scholar
• Hicks JK, Crews KR, Flynn P, et al. Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes. Pharmacogenomics. 2014 Jun;15(8):1065–1078. PMID: 25084200; PMCID: PMC4155516.
   PubMed Web of Science ®Google Scholar
• Moriyama B, Obeng AO, Barbarino J, et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy. Clin Pharmacol Ther. 2017 Jul;102(1):45–51. Epub 2017 Apr 18. Erratum in: Clin Pharmacol Ther. 2018 Feb;103(2):349. PMID: 27981572; PMCID: PMC5474211.
   PubMed Web of Science ®Google Scholar
• Dutch Pharmacogenetics Working Group. Pharmacogenetic recommendations; 2020. [cited 2020 Nov 1]. Available from: https://www.knmp.nl/@@search.
   Google Scholar
• Monserrat Villatoro J, García García I, Bueno D, et al. Randomised multicentre clinical trial to evaluate voriconazole pre-emptive genotyping strategy in patients with risk of aspergillosis: vorigenipharm study protocol. BMJ Open. 2020 Oct 1;10(10):e037443. PMID: 33004392; PMCID: PMC7534724.
   PubMed Web of Science ®Google Scholar
• Miller MA, Lee YM. Applying pharmacogenomics to antifungal selection and dosing: are we there yet? Curr Fungal Infect Rep. 2020 Mar;14(1):63–75. Epub 2020 Jan 16. PMID: 32256938; PMCID: PMC7111498.
   PubMed Web of Science ®Google Scholar
• Gautier-Veyret E, Thiebaut-Bertrand A, Roustit M, et al. Optimization of voriconazole therapy for treatment of invasive aspergillosis: pharmacogenomics and inflammatory status need to be evaluated. Br J Clin Pharmacol. 2020 Nov 20. Epub ahead of print. PMID: 33217017. DOI:10.1111/bcp.14661
   Web of Science ®Google Scholar